KR930701607A - 하이브리드 플라스미노겐 활성제 - Google Patents

하이브리드 플라스미노겐 활성제

Info

Publication number
KR930701607A
KR930701607A KR1019920703217A KR920703217A KR930701607A KR 930701607 A KR930701607 A KR 930701607A KR 1019920703217 A KR1019920703217 A KR 1019920703217A KR 920703217 A KR920703217 A KR 920703217A KR 930701607 A KR930701607 A KR 930701607A
Authority
KR
South Korea
Prior art keywords
compound according
glu
plasminogen
compound
modifications
Prior art date
Application number
KR1019920703217A
Other languages
English (en)
Inventor
휴우 로빈슨 제프리
Original Assignee
데이빗 로버츠
비이참 그루우프 피이엘시이
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 데이빗 로버츠, 비이참 그루우프 피이엘시이 filed Critical 데이빗 로버츠
Publication of KR930701607A publication Critical patent/KR930701607A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

하이브리드 섬유소 용해 효소, 그의 제조, 그를 함유하는 약제 조성물 및 혈전색전 질환, 상세하게는 급성심근경색증의 치료에서 그의 사용.

Description

하이브리드 플라스미노겐 활성제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 플리스미드 PSV2dhfr, 제2도 플라스미드 BPV-MT-Xhlo, 제3도 플라스미드 pTRH69, 제4도 플라스미드 pTRH70, 제5도 플라스미드 pTRH13

Claims (12)

1개 및 2개 사슬 변형, 1ys78및 glu1변형, 및 그의 혼합물을 포함하는 4-메톡시벤조일 플라스미노겐 1-541/t-PA 262-527.
4-메톡시벤조일 플라스미노겐 1-541/t-PA 262-527 glu1, 단일사슬 변형.
Glu1, 단일사슬 플라스미노겐 1-541/t-PA 262-527.
임의의 상기 항에 있어서, 앞에서 상기 실시예를 참고로 설명한 바와 실질적으로 동일한 화합물.
제약학적으로 허용가능한 부형제와 함께 제1 내지 4항중 임의의 한 항에 따른 화합물로 구성되는 약제 조성물.
제1 내지 4항중 임의의 한 항에 있어서, 활성 치료물질로서 사용하기 위한 화합물.
제1 내지 4항중 임의의 한 항에 있어서, 혈전증 질환의 치료에서 사용하기 위한 화합물.
혈전증 질환 치료를 위한 약제재료를 위해 제1 내지 4항중 임의의 한 항에 따른 화합물의 사용.
제1 내지 4항중 임의의 한 항에 따른 화합물의 유효 무독성 양을 환자에게 투여함으로 구성되는 혈전증 질환의 치료방법.
1개 및 2개의 사슬 변형, 1ys78및 glu1변형, 및 그의 혼합물을 포함하는 플라스미노겐 1-541/t-PA 262-527을, J가 효소의 촉매부위에 대한 제제의 결합을 매개하는 정위기이고 K는 p-메톡시벤조일기인 차단제 JK와 반응시킴으로 구성되는, 제1항 또는 2항에 따른 화합물의 제조 방법.
화합물을 암호하는 DNA를 숙주세포에서 발현시키고 생산물을 회수함으로 구성되는, 제3항에 따른 화합물의 제조방법.
※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019920703217A 1990-06-14 1991-06-12 하이브리드 플라스미노겐 활성제 KR930701607A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB909013345A GB9013345D0 (en) 1990-06-14 1990-06-14 Novel compounds
GB9013345.5 1990-06-14
PCT/GB1991/000945 WO1991019793A2 (en) 1990-06-14 1991-06-12 Hybrid plasminogen activators

Publications (1)

Publication Number Publication Date
KR930701607A true KR930701607A (ko) 1993-06-12

Family

ID=10677652

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920703217A KR930701607A (ko) 1990-06-14 1991-06-12 하이브리드 플라스미노겐 활성제

Country Status (12)

Country Link
EP (1) EP0535037A1 (ko)
JP (1) JPH05506363A (ko)
KR (1) KR930701607A (ko)
AU (1) AU648567B2 (ko)
CA (1) CA2085224A1 (ko)
GB (1) GB9013345D0 (ko)
IE (1) IE911999A1 (ko)
IL (1) IL98478A0 (ko)
NZ (1) NZ238506A (ko)
PT (1) PT97983A (ko)
WO (1) WO1991019793A2 (ko)
ZA (1) ZA914520B (ko)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3888099A (en) * 1998-12-02 2000-06-19 Oklahoma Medical Research Foundation Human plasminogen activator

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ191320A (en) * 1978-09-07 1982-09-14 Beecham Group Ltd In vivo fibrinolytic enzyme having active site blocked by hydrolytically removable group pharmaceutical compositions
GB8334498D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Compounds
DK359888A (da) * 1987-07-01 1989-01-02 Beecham Group Plc Fibrinolytisk enzym
GB9019120D0 (en) * 1990-09-01 1990-10-17 Beecham Group Plc Novel compounds

Also Published As

Publication number Publication date
NZ238506A (en) 1993-07-27
ZA914520B (en) 1992-12-30
IE911999A1 (en) 1991-12-18
GB9013345D0 (en) 1990-08-08
PT97983A (pt) 1992-04-30
WO1991019793A3 (en) 1992-01-23
JPH05506363A (ja) 1993-09-22
AU648567B2 (en) 1994-04-28
IL98478A0 (en) 1992-07-15
EP0535037A1 (en) 1993-04-07
AU8068191A (en) 1992-01-07
CA2085224A1 (en) 1991-12-15
WO1991019793A2 (en) 1991-12-26

Similar Documents

Publication Publication Date Title
DE69015182T2 (de) Thrombus-gerichtete komplexe, die aus plasminogenaktivator und fibrinfragmenten zusammengesetzt sind.
DK158994B (da) Analogifremgangsmaade til fremstilling af enzymderivater indeholdende et streptokinase/plasminogen-kompleks
SE8504945L (sv) Farmaceutiska kompositioner innehallande antracyklinglykosider
CH637992A5 (de) Verfahren zur herstellung eines komplexes aus streptokinase und einer leichten (b) plasmin-kettenfraktion mit einem aktiven serinprotease-zentrum.
FI905919A (fi) Foerfarande och material foer expression av en human plasminogenvariant.
KR900701832A (ko) 항-트롬빈
ES555118A0 (es) Metodo de preparar medicamentos que incluyen un agente buscador de hueso y un inhibidor de anhidrasa carbonica, para impedir y curar enfermedades oseas.
HK1007333A1 (en) Variants of plasminogen activatos and processes for their production
FI872831A (fi) Foerfarande foer framstaellning av farmaceutiska kompositioner.
KR930701607A (ko) 하이브리드 플라스미노겐 활성제
JPS58185526A (ja) 酵素誘導体、その製法及びそれを含む製薬組成物
SE8702562D0 (sv) Novel fibrinolytic enzymes
ATE147623T1 (de) Arzneizubereitung zum herstellen eines stabilisierten pulvers das eine kombination aus acetylsalicylsäure und metoclopramid als wirkstoff enthält
KR900702018A (ko) 단백질과 핵산
US5051264A (en) Potentiation of the thrombolytic effect of prourokinase type plasminogen activators by streptokinase
JP2004534837A (ja) 架橋したかつ共有結合したウロキナーゼ型プラスミノゲン活性化因子（ｓｃｕＰＡ）−ウロキナーゼ型プラスミノゲン活性化因子受容体（ｓｕＰＡＲ）複合体の線維素溶解剤としての使用
PT80214A (en) Process for the preparation of a pharmaceutical composition containing 9alpha,11beta-dichloro 16alpha-methyl 21-oxycarbonyldicyclohexyl-methyloxi-pregne-1,4-diene 3,20-dione as active agent and an inert product as excipient appropriate to permit r said composition to be used in the rectum or colon
ES2039194T3 (es) Un metodo de preparar una composicion farmaceutica tromboliticamente activa.
Thomson New thrombolytic drugs
KR890012940A (ko) 1-(4-아미노페닐)-2-헥사메틸렌이미노프로파논, 이의 제조방법 및 치료적 용도
ATE80308T1 (de) Thrombotische zusammensetzungen.
JPS61236730A (ja) プラスミノーゲン・アクチベータを含有する医薬
Verstraete Thrombolysis: an approach still on the move
DD299155A5 (de) Pharmazeutische zubereitungen
Lew Botulinum toxin type B (Myobloc™, NeuroBloc™): a new choice in cervical dystonia

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid